(-)-Pentazocine induces visceral chemical antinociception, but not thermal, mechanical, or somatic chemical antinociception, in μ-opioid receptor knockout mice

Molecular Pain

Kazutaka Ikeda⁴  Ichiro Sora¹  Masamichi Satoh²  George R Uhl⁵  Masabumi Minami³  Soichiro Ide⁴ 

[1] Division of Psychobiology, Department of Neuroscience, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan;Department of Pharmacy, Yasuda Women's University, Hiroshima 731-0153, Japan;Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan;Research Project for Addictive Substances, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan;Molecular Neurobiology, National Institute on Drug Abuse, Baltimore, Maryland 21224, USA

关键词: Antinociception;    Pentazocine;    Knockout mice;    Opioid receptor;   

Others  :  866232
DOI  :  10.1186/1744-8069-7-23

 received in 2011-02-07, accepted in 2011-04-10,  发布年份 2011

【 摘 要 】

Background

(-)-Pentazocine has been hypothesized to induce analgesia via the κ-opioid (KOP) receptor, although the involvement of other opioid receptor subtypes in the effects of pentazocine remains unknown. In this study, we investigated the role of the μ-opioid (MOP) receptor in thermal, mechanical, and chemical antinociception induced by (-)-pentazocine using MOP receptor knockout (MOP-KO) mice.

Results

(-)-Pentazocine-induced thermal antinociception, assessed by the hot-plate and tail-flick tests, was significantly reduced in heterozygous and abolished in homozygous MOP-KO mice compared with wildtype mice. The results obtained from the (-)-pentazocine-induced mechanical and somatic chemical antinociception experiments, which used the hind-paw pressure and formalin tests, were similar to the results obtained from the thermal antinociception experiments in these mice. However, (-)-pentazocine retained its ability to induce significant visceral chemical antinociception, assessed by the writhing test, in homozygous MOP-KO mice, an effect that was completely blocked by pretreatment with nor-binaltorphimine, a KOP receptor antagonist. In vitro binding and cyclic adenosine monophosphate assays showed that (-)-pentazocine possessed higher affinity for KOP and MOP receptors than for δ-opioid receptors.

Conclusions

The present study demonstrated the abolition of the thermal, mechanical, and somatic chemical antinociceptive effects of (-)-pentazocine and retention of the visceral chemical antinociceptive effects of (-)-pentazocine in MOP-KO mice. These results suggest that the MOP receptor plays a pivotal role in thermal, mechanical, and somatic chemical antinociception induced by (-)-pentazocine, whereas the KOP receptor is involved in visceral chemical antinociception induced by (-)-pentazocine.

【 授权许可】

   
2011 Ide et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Gutstein H, Akil H: Opioid analgesics. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th edition. Edited by Hardman JG, Limbird LE, Goodman-Gilman A. New York: McGraw-Hill; 2001:569-619.
• [2]Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a σ receptor system. Eur J Pharmacol 1995, 294:303-308.
• [3]Suzuki T, Narita M, Misawa M, Nagase H: Pentazocine-induced biphasic analgesia in mice. Life Sci 1991, 48:1827-1835.
• [4]Bidlack JM, McLaughlin JP, Wentland MP: Partial opioids: medications for the treatment of pain and drug abuse. Ann N Y Acad Sci 2000, 909:1-11.
• [5]Newman LC, Sands SS, Wallace DR, Stevens CW: Characterization of μ, κ, and δ opioid binding in amphibian whole brain tissue homogenates. J Pharmacol Exp Ther 2002, 301:364-370.
• [6]Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 1996, 383:819-823.
• [7]Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR: Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997, 94:1544-1549.
• [8]Sora I, Elmer G, Funada M, Pieper J, Li XF, Hall FS, Uhl GR: μ Opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo μ receptor reserve. Neuropsychopharmacology 2001, 25:41-54.
• [9]Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN: μ Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res 1998, 54:321-326.
• [10]Ide S, Minami M, Satoh M, Uhl GR, Sora I, Ikeda K: Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in μ-opioid receptor knockout mice. Neuropsychopharmacology 2004, 29:1656-1663.
• [11]Ide S, Minami M, Ishihara K, Uhl GR, Satoh M, Sora I, Ikeda K: Abolished thermal and mechanical antinociception but retained visceral chemical antinociception induced by butorphanol in μ-opioid receptor knockout mice. Neuropharmacology 2008, 54:1182-1188.
• [12]Woolfe G, MacDonald A: The evaluation of the analgesic action of pethidine hydrochloride (demerol). J Pharmacol Exp Ther 1944, 80:300-307.
• [13]D'Amour F, Smith D: A method for determining loss of pain sensation. J Pharmacol 1941, 72:74-79.
• [14]Randall LO, Selitto JJ: A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957, 111:409-419.
• [15]Collier HO, Dinneen LC, Johnson CA, Schneider C: The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br J Pharmacol Chemother 1968, 32:295-310.
• [16]Tanimoto S, Nakagawa T, Yamauchi Y, Minami M, Satoh M: Differential contributions of the basolateral and central nuclei of the amygdala in the negative affective component of chemical somatic and visceral pains in rats. Eur J Neurosci 2003, 18:2343-2350.
• [17]Katsumata S, Minami M, Nakagawa T, Iwamura T, Satoh M: Pharmacological study of dihydroetorphine in cloned μ-, δ- and κ-opioid receptors. Eur J Pharmacol 1995, 291:367-373.
• [18]Mogil JS, Chesler EJ, Wilson SG, Juraska JM, Sternberg WF: Sex differences in thermal nociception and morphine antinociception in rodents depend on genotype. Neurosci Biobehav Rev 2000, 24:375-389.
• [19]Birch PJ, Hayes AG, Sheehan MJ, Tyers MB: Norbinaltorphimine: antagonist profile at κ opioid receptors. Eur J Pharmacol 1987, 144:405-408.
• [20]Spanagel R, Almeida OF, Shippenberg TS: Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes. Eur J Pharmacol 1994, 264:157-162.
• [21]Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, Pintar JE: Retention of supraspinal δ-like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice. Neuron 1999, 24:243-252.
• [22]Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, Le Meur M, Roques BP, Maldonado R, Kieffer BL: Disruption of the κ-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 1998, 17:886-897.
• [23]Larsson MH, Bayati A, Lindstrom E, Larsson H: Involvement of kappa-opioid receptors in visceral nociception in mice. Neurogastroenterol Motil 2008, 20:1157-1164.
• [24]Riviere PJ: Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol 2004, 141:1331-1334.
• [25]Al-Chaer ED, Traub RJ: Biological basis of visceral pain: recent developments. Pain 2002, 96:221-225.
• [26]Sengupta JN, Su X, Gebhart GF: Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology 1996, 111:968-980.
• [27]Mogil JS, Wilson SG, Chesler EJ, Rankin AL, Nemmani KV, Lariviere WR, Groce MK, Wallace MR, Kaplan L, Staud R, Ness TJ, Glover TL, Stankova M, Mayorov A, Hruby VJ, Grisel JE, Fillingim RB: The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 2003, 100:4867-4872.
• [28]Craft RM, Bernal SA: Sex differences in opioid antinociception: κ and 'mixed action' agonists. Drug Alcohol Depend 2001, 63:215-228.
• [29]Kest B, Palmese C, Hopkins E: A comparison of morphine analgesic tolerance in male and female mice. Brain Res 2000, 879:17-22.
• [30]Bobeck EN, McNeal AL, Morgan MM: Drug dependent sex-differences in periaqueducatal gray mediated antinociception in the rat. Pain 2009, 147:210-216.
• [31]Craft RM, Ulibarri C, Leitl MD, Sumner JE: Dose- and time-dependent estradiol modulation of morphine antinociception in adult female rats. Eur J Pain 2008, 12:472-479.
• [32]Negus SS, Mello NK: Opioid antinociception in ovariectomized monkeys: comparison with antinociception in males and effects of estradiol replacement. J Pharmacol Exp Ther 1999, 290:1132-1140.
• [33]Aubrun F, Salvi N, Coriat P, Riou B: Sex- and age-related differences in morphine requirements for postoperative pain relief. Anesthesiology 2005, 103:156-160.
• [34]Fukuda K, Hayashida M, Ide S, Saita N, Kokita Y, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Nagashima M, Tagami M, Komatsu H, Sora I, Koga H, Kaneko Y, Ikeda K: Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain 2009, 147:194-201.
• [35]Gear RW, Gordon NC, Heller PH, Paul S, Miaskowski C, Levine JD: Gender difference in analgesic response to the kappa-opioid pentazocine. Neurosci Lett 1996, 205:207-209.
• [36]Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med 1996, 2:1248-1250.
• [37]Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 1999, 83:339-345.